arrow
B

Brad S. Kahl

washington university in st louis
H指数:74
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term survival and cause-specific mortality after event-free survival at 24 months (EFS24) in mantle cell lymphoma: an international multicohort study

套细胞淋巴瘤在24个月无事件生存期(EFS24)后的长期生存和特定病因死亡率:一项国际多队列研究

2026-09-220
OAAI
Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial

维奈克拉联合剂量调整的EPOCH-R方案治疗新诊断的双打击淋巴瘤:来自ALLIANCE A051701开放标签、随机对照、II-III期试验的II期结果

2026-08-010
PRE
Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826)

EBV状态和组织学对纳武利尤单抗-AVD与博安拉塞-AVD在晚期经典霍奇金淋巴瘤中患者预后的影响(S1826)

2026-07-310
OA
Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma

移植后 Brentuximab Vedotin 维持治疗在复发/难治性经典霍奇金淋巴瘤中的疗效:基于移植前疾病状态的分析

2026-06-250
OAAI
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

套细胞淋巴瘤在序贯一线 bendamustine-rituximab 和二线 Bruton 酪氨酸激酶抑制剂治疗后的预后

2026-04-250
OAAI
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma

伊匹木单抗、纳武利尤单抗和 Brentuximab Vedotin 治疗复发霍奇金淋巴瘤的随机二期研究

Blood
IF23.1
2026-04-011
PRE
Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 2.2026 Featured Updates to the NCCN Guidelines

NCCN Guidelines® 要点:慢性淋巴细胞白血病/小淋巴细胞淋巴瘤,版本 2.2026

2026-03-013
PRE
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma

利妥昔单抗维持治疗在一线苯达莫司汀联合利妥昔单抗治疗后滤泡性淋巴瘤患者中的获益

2025-12-150
OAAI
Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

2024年国际滤泡性淋巴瘤科学研讨会共识建议

2025-12-050
OAAI
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure

基于先前CD19定向CAR T暴露的大B细胞淋巴瘤中Tafasitamab和Lenalidomide的治疗效果

2025-11-180
OAAI
Social Genomic Mechanisms of Health Disparities Among Adolescent/Young Adult Survivors of Hodgkin and Non-Hodgkin Lymphoma: ECOG-ACRIN E

健康不平等的社会基因组机制:霍奇金和非霍奇金淋巴瘤青少年/青年成年幸存者研究:ECOG-ACRIN E

2025-11-010
PRE
Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort study
2025-11-010
PRE
Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort

自评生成的Charlson合并症指数在淋巴瘤结局流行病学(LEO)队列中的适应性和表现

2025-10-070
PRE
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies

多中心研究:ALK阳性大B细胞淋巴瘤:ALK抑制剂和生物学指导治疗时代的结局

2025-09-030
PRE
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts

滤泡性淋巴瘤3B亚型具有不同的预后结局:来自前瞻性多中心MER和LEO队列的研究结果

2025-08-080
OAAI
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403

II期研究:将venetoclax加入bendamustine和obinutuzumab用于高风险滤泡性淋巴瘤患者的一线治疗:PrE0403

2025-05-120
OA
The Phenotypic Landscape of Anaplastic Large Cell Lymphoma Supports a New Molecular Classification: An LLMPP Study

间变性大细胞淋巴瘤的表型景观支持新的分子分类: 一项LLMPP研究

2025-03-010
PRE
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study

R-gemox治疗复发或难治性弥漫性大b细胞淋巴瘤的疗效: 一项多中心队列研究

2025-02-070
PRE
Vitamin D in patients with low tumor-burden indolent non- Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial
2024-12-011
OAAI